{"id":"engerix-b","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site soreness or swelling"},{"rate":"1-6","effect":"Fever"},{"rate":"1-5","effect":"Fatigue"},{"rate":"1-5","effect":"Headache"},{"rate":"1-3","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL1160385","moleculeType":"Small molecule","molecularWeight":"182.27"},"_dailymed":{"setId":"dcecf9e0-6c28-4964-9ddb-9379705fa26c","title":"ENGERIX-B (HEPATITIS B VACCINE (RECOMBINANT)) INJECTION, SUSPENSION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant hepatitis B surface antigen produced in yeast cells, which is adsorbed onto aluminum hydroxide as an adjuvant. When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (anti-HBs) and memory B cells that provide long-term immunity against hepatitis B virus infection.","oneSentence":"Engerix B is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:00.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in infants, children, and adults"},{"name":"Post-exposure prophylaxis for hepatitis B"}]},"trialDetails":[{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT04193189","phase":"PHASE3","title":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-14","conditions":"HIV Infection, Hepatitis B","enrollment":638},{"nctId":"NCT05482295","phase":"PHASE3","title":"Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-09","conditions":"Vaccine Reaction, Vaccine Adverse Reaction","enrollment":540},{"nctId":"NCT04970836","phase":"NA","title":"The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-08-01","conditions":"Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine","enrollment":240},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06515938","phase":"NA","title":"Study on New Strategies for Hepatitis B Virus Immunization","status":"COMPLETED","sponsor":"Wu Jiang","startDate":"2013-01-01","conditions":"Vaccine Reaction","enrollment":1169},{"nctId":"NCT04456504","phase":"PHASE4","title":"HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-09-15","conditions":"Healthcare Worker, Hepatitis B Vaccine, Nonresponder","enrollment":49},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT01311674","phase":"PHASE3","title":"Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)","status":"TERMINATED","sponsor":"Emergent BioSolutions","startDate":"2009-09","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT05200338","phase":"NA","title":"Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-06-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT02434848","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-07-23","conditions":"HIV, Communicable Diseases, Hepatitis B","enrollment":13},{"nctId":"NCT01251276","phase":"PHASE3","title":"Hepatitis B Challenge Dose in Adults (V232-059-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-30","conditions":"Hepatitis B","enrollment":204},{"nctId":"NCT04531098","phase":"PHASE3","title":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2006-03-02","conditions":"Hepatitis B","enrollment":402},{"nctId":"NCT04209400","phase":"PHASE3","title":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2014-04-18","conditions":"Hepatitis B","enrollment":100},{"nctId":"NCT04072211","phase":"PHASE4","title":"Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-11-25","conditions":"Hepatitis B Virus, Health Care Associated Infection","enrollment":641},{"nctId":"NCT04083157","phase":"PHASE2, PHASE3","title":"Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-08-12","conditions":"Inflammatory Bowel Diseases, Hepatitis B","enrollment":104},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03627507","phase":"PHASE2, PHASE3","title":"Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-29","conditions":"Hepatitis B Infection","enrollment":158},{"nctId":"NCT02985450","phase":"","title":"A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-08","conditions":"Non-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction","enrollment":82},{"nctId":"NCT00985426","phase":"PHASE3","title":"Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":521},{"nctId":"NCT04870021","phase":"PHASE4","title":"Hepatitis B Birth Dose for Newborns","status":"COMPLETED","sponsor":"Quaid-e-Azam University","startDate":"2015-03-15","conditions":"Hepatitis B, Immunization; Infection","enrollment":218},{"nctId":"NCT03408730","phase":"PHASE3","title":"Lot-to-lot Consistency of Sci-B-Vac™ in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-14","conditions":"Hepatitis B Vaccines","enrollment":2838},{"nctId":"NCT01311024","phase":"","title":"Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage","status":"COMPLETED","sponsor":"Arto Palmu","startDate":"2011-04","conditions":"Pneumococcal Infections","enrollment":2341},{"nctId":"NCT03567382","phase":"PHASE4","title":"Arresting Vertical Transmission of Hepatitis B Virus","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-09-24","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":179},{"nctId":"NCT00839254","phase":"PHASE3","title":"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-18","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":6181},{"nctId":"NCT00861380","phase":"PHASE3","title":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-04","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":41188},{"nctId":"NCT03083158","phase":"PHASE4","title":"Immunity to Hepatitis B Vaccine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-03-06","conditions":"Hepatitis B, Immunization; Infection","enrollment":16},{"nctId":"NCT00289185","phase":"PHASE2","title":"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-27","conditions":"Malaria, Malaria Vaccines","enrollment":340},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT03393754","phase":"PHASE3","title":"Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-13","conditions":"Hepatitis B Vaccines","enrollment":1607},{"nctId":"NCT03854630","phase":"PHASE4","title":"Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-09-06","conditions":"Viral Hepatitis B, Immunization; Infection, HIV Infections","enrollment":575},{"nctId":"NCT01531075","phase":"NA","title":"Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2012-04","conditions":"Inflammatory Bowel Disease","enrollment":91},{"nctId":"NCT04326803","phase":"PHASE4","title":"Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-06-01","conditions":"Hepatitis B","enrollment":200},{"nctId":"NCT02798952","phase":"PHASE4","title":"A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-23","conditions":"Hepatitis B","enrollment":302},{"nctId":"NCT00637195","phase":"PHASE3","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-11","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":152},{"nctId":"NCT02901951","phase":"PHASE4","title":"Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-11","conditions":"Hepatitis B Vaccine","enrollment":106},{"nctId":"NCT02096263","phase":"PHASE3","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-16","conditions":"Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b","enrollment":585},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":"Hepatitis B, Hepatitis A","enrollment":596},{"nctId":"NCT00534638","phase":"PHASE4","title":"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-04","conditions":"Infections, Papillomavirus","enrollment":34412},{"nctId":"NCT02505009","phase":"PHASE4","title":"Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2015-05-01","conditions":"Chronic Hepatitis B","enrollment":116},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT00343915","phase":"PHASE3","title":"Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-21","conditions":"Hepatitis B","enrollment":267},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01282762","phase":"","title":"Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"Chronic Kidney Disease","enrollment":147},{"nctId":"NCT00435812","phase":"PHASE3","title":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-12","conditions":"Hepatitis B","enrollment":2428},{"nctId":"NCT01195246","phase":"PHASE3","title":"Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"End Stage Renal Disease","enrollment":155},{"nctId":"NCT01005407","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-02","conditions":"Healthy","enrollment":2452},{"nctId":"NCT00426712","phase":"PHASE1","title":"Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-01","conditions":"Hepatitis B","enrollment":42},{"nctId":"NCT01037114","phase":"PHASE4","title":"Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-27","conditions":"Hepatitis A, Hepatitis B","enrollment":50},{"nctId":"NCT02003703","phase":"PHASE3","title":"Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .","status":"COMPLETED","sponsor":"Universidad de Valparaiso","startDate":"2015-05","conditions":"Hepatitis B, HIV","enrollment":107},{"nctId":"NCT01777295","phase":"PHASE2","title":"Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-25","conditions":"Hepatitis B","enrollment":81},{"nctId":"NCT00309166","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-05","conditions":"Infections, Papillomavirus","enrollment":270},{"nctId":"NCT00524576","phase":"PHASE4","title":"Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-28","conditions":"Hepatitis B","enrollment":144},{"nctId":"NCT01000324","phase":"PHASE4","title":"Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-06","conditions":"Hepatitis A, Hepatitis B","enrollment":44},{"nctId":"NCT00984139","phase":"PHASE4","title":"Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Hepatitis B","enrollment":306},{"nctId":"NCT00805389","phase":"PHASE2","title":"Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12-15","conditions":"Hepatitis B","enrollment":713},{"nctId":"NCT00289744","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02-16","conditions":"Hepatitis B, Hepatitis A","enrollment":178},{"nctId":"NCT01138098","phase":"PHASE4","title":"Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-07","conditions":"Hepatitis B","enrollment":185},{"nctId":"NCT00197028","phase":"PHASE2","title":"Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08-23","conditions":"Malaria","enrollment":214},{"nctId":"NCT01847430","phase":"PHASE4","title":"Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-19","conditions":"Hepatitis B","enrollment":303},{"nctId":"NCT00684671","phase":"PHASE4","title":"Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-26","conditions":"Hepatitis A, Hepatitis B","enrollment":506},{"nctId":"NCT00652938","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-09","conditions":"Infections, Papillomavirus","enrollment":744},{"nctId":"NCT00519649","phase":"PHASE4","title":"Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-31","conditions":"Hepatitis B Vaccine","enrollment":301},{"nctId":"NCT01277042","phase":"PHASE3","title":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Papillomavirus","enrollment":1212},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT00814489","phase":"PHASE1","title":"Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-08","conditions":"Streptococcus Pneumoniae, Haemophilus Influenzae","enrollment":40},{"nctId":"NCT01627340","phase":"PHASE4","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-24","conditions":"Hepatitis B","enrollment":667},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":"Haemophilus Influenzae Type b","enrollment":4003},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT01333813","phase":"PHASE4","title":"Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-26","conditions":"Hepatitis B","enrollment":300},{"nctId":"NCT02052661","phase":"PHASE4","title":"This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-18","conditions":"Hepatitis B","enrollment":301},{"nctId":"NCT03405597","phase":"PHASE3","title":"HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2017-03-30","conditions":"Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine","enrollment":97},{"nctId":"NCT00873652","phase":"","title":"Observational Study of Immune Response to Hepatitis B Childhood Booster","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT00693186","phase":"PHASE3","title":"A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Hepatitis B","enrollment":410},{"nctId":"NCT01457495","phase":"PHASE2","title":"Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib)","enrollment":312},{"nctId":"NCT00698061","phase":"PHASE3","title":"Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-11","conditions":"Hepatitis B","enrollment":145},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT01817725","phase":"PHASE1","title":"Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-03","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT00440297","phase":"PHASE3","title":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis B Virus Infection","enrollment":277},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Hepatitis B","enrollment":540},{"nctId":"NCT00393523","phase":"PHASE3","title":"Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hepatitis B","enrollment":1478},{"nctId":"NCT00106964","phase":"PHASE4","title":"Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B","enrollment":371},{"nctId":"NCT00383591","phase":"PHASE3","title":"Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":"Hepatitis B","enrollment":120},{"nctId":"NCT00603252","phase":"PHASE4","title":"Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Hepatitis B, Hepatitis A","enrollment":213},{"nctId":"NCT00142753","phase":"PHASE4","title":"Immunologic Memory (Supp. of ATN 024)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-08","conditions":"HIV Infections","enrollment":95},{"nctId":"NCT00841477","phase":"PHASE3","title":"An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2004-01","conditions":"Hepatitis B Infection, Hepatitis C Infection, HIV Infection","enrollment":1260},{"nctId":"NCT00657657","phase":"PHASE4","title":"Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04","conditions":"Hepatitis B","enrollment":29},{"nctId":"NCT00240500","phase":"PHASE4","title":"Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B","enrollment":109},{"nctId":"NCT00456625","phase":"PHASE4","title":"Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Hepatitis B","enrollment":76},{"nctId":"NCT00323622","phase":"PHASE2","title":"Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Malaria","enrollment":1737},{"nctId":"NCT00240539","phase":"PHASE4","title":"Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["There are no other names."],"phase":"marketed","status":"active","brandName":"Engerix B","genericName":"Engerix B","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","modality":"Biologic","firstApprovalDate":"","aiSummary":"Engerix B is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg). Used for Prevention of hepatitis B infection in infants, children, and adults, Post-exposure prophylaxis for hepatitis B.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}